NCT03197259 (CLLTRegistry) is a clinical trial in Chronic Lymphocytic Leukemia, sponsored by Fatih Demirkan, MD.

Who is sponsoring NCT03197259?

NCT03197259 is sponsored by Fatih Demirkan, MD.

What condition does NCT03197259 study?

NCT03197259 studies Chronic Lymphocytic Leukemia, Del(17P).

Is NCT03197259 still recruiting?

NCT03197259 is currently recruiting now. Last updated 9 March 2021.

Last reviewed 2021-03-09 · How we verify

NCT03197259: CLLTRegistry

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chronic Lymphocytic Leukemia Registry Study - Multicenter Prospective National Study

Recruiting now Last updated 9 March 2021

What this trial tests

trial in Chronic Lymphocytic Leukemia in 1,000 participants. Currently enrolling.

Timeline

1 January 2017

Primary endpoint
1 January 2023

1 August 2026

Quick facts

Lead sponsor	Fatih Demirkan, MD
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	1,000
Start date	1 January 2017
Primary completion	1 January 2023
Estimated completion	1 August 2026
Sites	1 location across Turkey (Türkiye)

Conditions studied

Chronic Lymphocytic Leukemia — all drugs for Chronic Lymphocytic Leukemia →
Del(17P) — all drugs for Del(17P) →

Sponsor

Fatih Demirkan, MD

Who can join

18 and older, any sex, with Chronic Lymphocytic Leukemia or Del(17P). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective, multicenter national observational study for patients diagnosed as chronic lymphocytic leukemia across 25 centers in Turkey

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Chronic Lymphocytic Leukemia

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT06863402 — Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype · Phase 2 · recruiting
NCT07218510 — Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Smal · Phase 2 · recruiting
NCT07288515 — Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus · recruiting
NCT07014917 — Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03197259 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fatih Demirkan, MD
Last refreshed: 9 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03197259.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing